Finding biomarkers for autoimmune responses in Alzheimer's disease.
Official title: Discovery and validation of biomarkers of autoimmunity in Alzheimer's Disease.
Funded at Sinai Health System · NIH-10990984 · Data updated 2026-11-12
This study is looking for special markers in the fluid around your brain that can help tell Alzheimer's apart from other brain diseases and track how it changes over time, which could lead to better ways to diagnose and manage the condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sinai Health System NIH-funded |
| Lab location | 1 site (Toronto, Canada) |
| Project start | February 15, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $228,042 |
| NIH project number | 5R21AG080575-02 |
| Project ID | NIH-10990984 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those exhibiting symptoms of neurodegenerative disorders.
✕Less likely to help
Patients with neurodegenerative disorders other than Alzheimer's disease may not benefit directly from this research.
What this research studies
This research aims to identify specific biomarkers that can help differentiate Alzheimer's disease from other neurodegenerative disorders and track its progression. By analyzing cerebrospinal fluid, the team will look for autoantibodies and immune complexes that may contribute to the disease. Using advanced mass spectrometry techniques, they will discover these biomarkers and develop targeted assays for further testing in both cerebrospinal fluid and serum. This approach could lead to more accurate diagnoses and better management of Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and monitoring methods for Alzheimer's disease, enhancing patient care.
How similar studies have gone: Previous research has shown promise in identifying biomarkers for other neurodegenerative diseases, suggesting potential success for this novel approach.
Where this research is happening
-
Sinai Health System
Toronto, Canada Active
Researchers
- Principal investigator: Diamandis, Eleftherios P — Sinai Health System
- Study coordinator: Diamandis, Eleftherios P
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.